Inpharma 1533 - 15 Apr 2006 Antithrombin III increases survival in high-risk sepsis patients High-dose antithrombin III (ATIII) may increase survival in patients with severe sepsis and a high risk of death, and could be even more effective without concurrent heparin treatment, according to an analysis of the multicentre KyberSept trial * . Data were evaluated from 1008 patients from the KyberSept population with severe sepsis and a SAPS II ** - predicted mortality rate of between 30% and 60%. These patients had been randomised to receive either IV ATIII 30 000 IU over 4 days (n = 490) or placebo. The survival rates were significantly higher over 90 days in ATIII-treated patients, compared with placebo recipients. In addition, ATIII-treated patients who did not receive concurrent heparin treatment showed an even greater improvement in survival rate over 90 days, compared with placebo recipients. There was a significantly higher incidence of bleeding events in patients who received ATIII, especially those treated with heparin, compared with patients in the placebo group. Notably, the increase in frequency of bleeding events in the ATIII-treated patients did not affect the significantly greater survival rate in this group. * See Inpharma 1311 p11; 800840911; partially supported by ZLB Behring GmBH, Germany ** Simplified Acute Physiology Score II Wiedermann CJ, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine 34: 285-292, No. 2, Feb 2006 801036324 1 Inpharma 15 Apr 2006 No. 1533 1173-8324/10/1533-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Antithrombin III increases survival in high-risk sepsis patients

Download PDF Report

View
212
Download
0

Embed Size (px)

Citation preview

Inpharma 1533 - 15 Apr 2006

Antithrombin III increases survivalin high-risk sepsis patients

High-dose antithrombin III (ATIII) may increasesurvival in patients with severe sepsis and a high risk ofdeath, and could be even more effective withoutconcurrent heparin treatment, according to an analysisof the multicentre KyberSept trial*.

Data were evaluated from 1008 patients from theKyberSept population with severe sepsis and a SAPS II**-predicted mortality rate of between 30% and 60%. Thesepatients had been randomised to receive either IV ATIII30 000 IU over 4 days (n = 490) or placebo.

The survival rates were significantly higher over90 days in ATIII-treated patients, compared with placeborecipients. In addition, ATIII-treated patients who didnot receive concurrent heparin treatment showed aneven greater improvement in survival rate over 90 days,compared with placebo recipients. There was asignificantly higher incidence of bleeding events inpatients who received ATIII, especially those treatedwith heparin, compared with patients in the placebogroup. Notably, the increase in frequency of bleedingevents in the ATIII-treated patients did not affect thesignificantly greater survival rate in this group.* See Inpharma 1311 p11; 800840911; partially supported by ZLBBehring GmBH, Germany** Simplified Acute Physiology Score II

Wiedermann CJ, et al. High-dose antithrombin III in the treatment of severe sepsisin patients with a high risk of death: efficacy and safety. Critical Care Medicine34: 285-292, No. 2, Feb 2006 801036324